Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANAND A PATEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1467870204
CMS profile
2060514
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$10,071.84

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,268.00 2
Food and Beverage $1,803.84 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $5,500.00 1
E.R. Squibb & Sons, L.L.C. $2,768.00 1
Celgene Corporation $1,803.84 3

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANAND A PATEL

NPI 1467870204 · CMS profile ID 2060514

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467870204?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANAND A PATEL, NPI 1467870204, CMS profile ID 2060514. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467870204?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANAND A PATEL, NPI 1467870204, CMS profile ID 2060514. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467870204?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANAND A PATEL, NPI 1467870204, CMS profile ID 2060514, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467870204?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $10,071.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $2,768.0012/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932598129 CMS
Celgene Corporation $1,235.6912/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932598145 CMS
Celgene Corporation $2.8212/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932598147 CMS
Celgene Corporation $565.3312/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932598149 CMS
ABBVIE INC. $5,500.0008/12/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891324297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $28.29 1
PY2022 $10,071.84 5
PY2023 $3,928.97 4
PY2024 $337.50 1
PY2025 $13,146.28 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,185,638.17 275
PY2024 Principal investigator $56,040.16 4
PY2023 Principal investigator $438,137.80 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

275 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656098
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656102
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656106
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656110
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656114
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656119
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656123
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656127
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656130
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656134
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656138
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656142
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656146
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656149
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656153
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656158
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $239,043.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976499
Principal investigator 1 Stemline Therapeutics Inc. $273.14 11/13/2025 Non-covered Recipient Entity
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Hyde Park
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244136103
Principal investigator 1 Stemline Therapeutics Inc. $342.06 10/23/2025 Non-covered Recipient Entity
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Hyde Park
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244136107
Principal investigator 1 Stemline Therapeutics Inc. $10.60 10/23/2025 Non-covered Recipient Entity
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Hyde Park
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244136111
Principal investigator 1 Stemline Therapeutics Inc. $20.83 10/23/2025 Non-covered Recipient Entity
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Hyde Park
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244136115
Principal investigator 1 Stemline Therapeutics Inc. $85.99 10/23/2025 Non-covered Recipient Entity
The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM Hyde Park
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244136119
Principal investigator 1 Celgene Corporation $11,175.00 09/18/2025 Non-covered Recipient Entity
The University Of Chicago Edward H Levi Hall
A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-91633 (BMS-986397) IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR RELAPSED OR REFRACTORY HIGHER-RISK MYELODYSPLASTIC SYNDROMES No dispute reported 06/30/2026 1222305898
Principal investigator 1 Incyte Corporation $82,699.00 08/25/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b trial of ruxolitinib combined with IDH1 inhibition in IDH1-mutated advanced-phase MPNs No dispute reported 06/30/2026 1240606313
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 08/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176643903
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 08/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176643907
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641933
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641936
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641941
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641945
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641949
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641953
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641957
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641961
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641965
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641969
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641973
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641978
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641983
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641987
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641991
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641995
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641999
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642002
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642006
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642009
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642013
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642018
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642021
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642025
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642029
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642033
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642035
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642039
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642043
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642047
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642052
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642056
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642059
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642063
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642066
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642070
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642074
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642078
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642083
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642087
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642090
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642094
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642098
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642102
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642107
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642111
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642115
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642119
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642123
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642127
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642131
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642135
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642138
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642142
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642146
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642149
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642153
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642157
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642161
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642165
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642169
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642173
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642177
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642181
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642184
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642188
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642192
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642195
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642198
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642203
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642207
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642211
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642215
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642219
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642223
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642227
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642231
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642236
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642240
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642243
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642247
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642249
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642252
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642257
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642260
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642264
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642268
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642271
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642276
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642281
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642285
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642290
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642294
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642298
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642302
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642306
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642310
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642314
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642318
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642322
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642326
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642331
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642334
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642338
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642342
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642346
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642350
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642356
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642362
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642367
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642371
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642375
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642380
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642384
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642387
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642392
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642396
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642400
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642404
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642408
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642412
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642416
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642419
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642423
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642427
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642432
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642436
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642440
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176642443
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $170,745.00 07/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976507
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $120,840.30 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976487
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $136,596.00 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976491
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $120,840.30 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976503
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176636817
Principal investigator 1 Sumitomo Pharma America, Inc. $10,554.70 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176635248
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $170,745.00 04/16/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs No dispute reported 06/30/2026 1235976495
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
University Of Chicago Cancer Center At Silver Cross
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235992669
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $79,967.43 04/07/2025 Non-covered Recipient Entity
The University Of Chicago Kovler Diabetes Center
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235993001
Principal investigator 1 Sumitomo Pharma America, Inc. $7,735.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176630752
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629212
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629216
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629220
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629225
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629229
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629232
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629236
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629241
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629245
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629248
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629252
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629258
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629262
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629266
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629269
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629274
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629278
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629281
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629285
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629289
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629293
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629297
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629301
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629305
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629309
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629313
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629317
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629321
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629326
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629330
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629333
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629338
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629341
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629346
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629350
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629355
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629358
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629362
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629365
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629369
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629373
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629377
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629381
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629385
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629389
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629393
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629396
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629399
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629403
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629408
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629411
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629416
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629421
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629425
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629428
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629432
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629436
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629439
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629443
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629447
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629450
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629455
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629459
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629463
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629466
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629470
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629473
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629477
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629481
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629485
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629489
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629491
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629495
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629498
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629502
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629506
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629509
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629513
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629517
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629522
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629527
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629530
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629534
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629539
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629543
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629546
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629549
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629553
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629558
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629562
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629566
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629570
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629574
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629577
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 03/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176629581
Principal investigator 1 Sumitomo Pharma America, Inc. $140.00 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176628360
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625109
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625112
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625115
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625118
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625122
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625126
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625131
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625135
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625139
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625143
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625147
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625151
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625155
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 02/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176625158